Tirzepatide 50 mg vial dosage

What Tirzepatide is

Class:

Dual GIP/GLP-1 receptor agonist

Also called:

Mounjaro, Zepbound

Used for:

FDA-approved to improve glycemic control in type 2 diabetes in adults and children 10 years and older, and to reduce cardiovascular risk in adults with type 2 diabetes (Mounjaro), and for chronic weight management and moderate-to-severe obstructive sleep apnoea in adults with obesity (Zepbound).

Human evidence:

Strong human evidence. FDA has approved tirzepatide products for four indications across two brands, each cleared on placebo-controlled randomised trials reviewed by the agency: glycemic control and cardiovascular risk reduction in type 2 diabetes (Mounjaro, approved 2022), and chronic weight management and obstructive sleep apnoea (Zepbound, approved from 2023). The adverse-reaction rates on the approved label come from that trial data. This rating describes the approved product, not grey-market vials sold under the same name.

Half-life:

Approximately 5 days, which the label states is what enables once-weekly dosing.

US status:

FDA-approved · prescription only. FDA-approved as Mounjaro and Zepbound, each with its own indication. Requires a prescriber. As with semaglutide, FDA has documented dosing errors, counterfeit product and fraudulent labelling in the compounded and "research use only" tirzepatide market, and retatrutide and cagrilintide - often sold alongside it - cannot legally be compounded at all.

The full picture, with every study: Tirzepatide guide.

How to mix a 50 mg Tirzepatide vial

For this vial: 1 mL of bacteriostatic water makes 50 mg/mL, so 10 mg is 20 units (0.2 mL) on a U-100 insulin syringe. Pick a different volume from the units table if you want bigger or smaller draws; the number of doses stays the same.

1. Wipe the rubber stoppers of both the peptide vial and the bacteriostatic water vial with an alcohol swab and let the alcohol dry. ^[2][3]
2. With a new sterile needle and syringe, draw up the amount of bacteriostatic water you have chosen for the dilution. ^[2][3][4]
3. Inject the water into the peptide vial by aiming the stream against the inside glass wall, which helps prevent foaming. ^[5]
4. Swirl or roll the vial gently until the powder has fully dissolved; do not shake it. Do not inject the solution if it is cloudy or has particles in it. ^[2][3][5]
5. Label the vial with the date and time it was mixed, the amount of water added and how long it can be used after mixing. ^[2]
6. Store the mixed vial in the refrigerator at 2-8°C (36-46°F) and do not freeze it. ^[5]

Step by step with pictures: how to reconstitute peptides. About the water itself: bacteriostatic water.

Storing Tirzepatide vials

• Freeze-dried (lyophilized) peptide keeps far longer than peptide in solution; peptide suppliers advise storing the powder at -20°C away from bright light. ^[6]
• Protect peptide vials from heat and light. ^[6][7]
• Avoid repeated freeze-thaw cycles; a prescription peptide label also says not to freeze a vial once it has been mixed. ^[5][6]
• Once a multi-dose vial, such as bacteriostatic water, has been opened (needle-punctured), date it and discard it within 28 days unless its manufacturer states another date. ^[8][9]

More detail: peptide storage and shelf life.

Injecting safely

• Clean the injection site with an alcohol swab and let the skin dry completely before injecting. ^[10][11]
• Pinch up a fold of skin and fat (not muscle) and insert the needle at a 45- to 90-degree angle: 90 degrees where there is enough fatty tissue, 45 degrees where there is little. ^[10][11][12]
• Pulling back on the plunger (aspiration) is not necessary for a subcutaneous injection, because the chance of the needle being in a blood vessel is small. ^[10]
• Inject slowly, at roughly 10 seconds per mL. ^[10]
• Common sites are the belly, the thigh and the upper arm; rotate sites, keeping each injection at least 1 inch (2.5 cm) from the last. ^[5][10][11]

Hygiene and warning signs

• Use a new sterile needle and syringe for every injection and every time you enter a vial; never reuse them. ^[4][8][11]
• Never share needles, syringes or pens with anyone, even if the needle is changed; unsafe injection practices spread hepatitis B, hepatitis C and HIV. ^[4][7][8]
• Put used needles and syringes in a sharps disposal container straight away (FDA-cleared if possible), never loose in the trash, recycling or toilet, and dispose of the container following your community's guidelines. ^[13][14]
• Contact a health care provider if the injection site shows signs of infection, such as redness, swelling, red streaks or a fever. ^[11]

Where to inject: subcutaneous injection sites.

How Tirzepatide works

• Tirzepatide is a peptide built on the GIP hormone sequence, with non-standard aminoisobutyric acid at positions 2 and 13 and a C20 fatty di-acid attached at lysine 20. The fatty acid lets it bind albumin, giving an elimination half-life of about 5 to 6 days. ^[15]
• It selectively binds and activates two receptors, GIP and GLP-1. Both receptors sit in brain areas that regulate appetite; GLP-1 is an established appetite regulator, and non-clinical studies suggest GIP adds to the effect on food intake. ^[15]
• It lowers calorie intake, and the weight it removes is more fat mass than lean mass. It also raises insulin release in a glucose-dependent way, lowers glucagon, and improved insulin sensitivity in a 28-week clamp study in type 2 diabetes. ^[15]
• It slows gastric emptying; the delay is greatest after the first dose and lessens over time. ^[15]

What the Tirzepatide research found

Human evidence: strong human evidence. Each result says what was studied.

• Human studyIn a 72-week randomised, placebo-controlled trial of 2,539 adults with obesity or overweight and no diabetes, body weight fell by 15.0%, 19.5% and 20.9% on the 5, 10 and 15 mg weekly doses, against 3.1% on placebo. ^[15]
• Human studyIn a 72-week trial of 938 adults with type 2 diabetes and a BMI of 27 or more, weight fell by 12.8% on 10 mg and 14.7% on 15 mg, against 3.2% on placebo. ^[15]
• Human studyIn two 52-week trials of 469 adults with obesity and moderate-to-severe obstructive sleep apnoea, the apnoea-hypopnoea index fell by 25.3 and 29.3 events per hour on tirzepatide, against about 5 events per hour on placebo. ^[15]
• Human studyIn the SURMOUNT-4 withdrawal trial, 670 adults who had lost a mean 20.9% over a 36-week lead-in were randomised to continue or switch to placebo. Over the next 52 weeks, those who continued lost a further 5.5% while those on placebo regained 14.0%. ^[16]
• Human studyIn SURMOUNT-5, an open-label 72-week head-to-head trial of 751 adults with obesity and no diabetes, weight fell by 20.2% on tirzepatide against 13.7% on semaglutide, each at its maximum tolerated dose. ^[17]

Tirzepatide side effects and risks

• FDA labelGastrointestinal effects are the most common. In two trials pooling 2,519 treated adults over up to 72 weeks, nausea affected 25%, 29% and 28% on 5, 10 and 15 mg against 8% on placebo; diarrhoea 19-23% vs 8%; vomiting 8-13% vs 2%; constipation 11-17% vs 5%. Adverse reactions led 4.8-6.7% to stop, against 3.4% on placebo. ^[15]
• FDA labelBoxed warning: in a 2-year rat study, tirzepatide caused dose- and duration-dependent thyroid C-cell tumours at clinically relevant exposures. Whether this happens in humans is unknown, and it is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. ^[15]
• FDA labelAcute pancreatitis, including fatal cases, has been seen with GLP-1-type drugs including tirzepatide. Cholecystitis was reported in 0.7% on tirzepatide against 0.2% on placebo, and gallbladder removal in 0.2% against none. ^[15]
• FDA labelIn adults with type 2 diabetes, low blood sugar (under 54 mg/dL) occurred in 4.2% on tirzepatide against 1.3% on placebo, rising to 10.3% in those also taking a sulfonylurea-type drug. ^[15]
• FDA labelSevere gastrointestinal reactions occurred in 1.7-3.1% across doses against 1% on placebo, and postmarketing reports describe acute kidney injury, sometimes needing dialysis, mostly after dehydration from vomiting or diarrhoea. It is not recommended with severe gastroparesis. ^[15]
• FDA labelInjection-site reactions affected 6-8% against 2% on placebo, and severe allergic reactions 0.1% against none; anaphylaxis and angioedema have been reported after approval. Rare reports describe food inhaled into the lungs during anaesthesia or deep sedation. ^[15]

Other things to know

• Boxed warning: causes thyroid C-cell tumours in rats; whether this occurs in humans is unknown. Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Gastrointestinal effects are the most common adverse reaction. At the 15 mg maintenance dose in the trial data behind the Zepbound label: nausea 28%, diarrhoea 23%, vomiting 13%, constipation 11%.
• Delays gastric emptying and can affect the absorption of other oral medicines taken around the same time.
• Neither semaglutide nor tirzepatide is on the 503B bulks list, so most compounding of either now falls outside the shortage-era exception that used to apply; FDA has received hundreds of adverse event reports tied to compounded tirzepatide specifically.

Reported side effects and what the studies measured: Tirzepatide side effects.

Where this vial size comes from

Tirzepatide is sold as a 50 mg vial by the page below, each checked on the date shown. I list them as evidence that this size exists, not as a recommendation to buy from them.

• PSPeptidesvendorLists it as: Vial size options include 50MG · checked 2026-09-28

The doses come from the FDA label on the Tirzepatide dosing page, and every number on this page is arithmetic on those doses and this vial size.

Other Tirzepatide vial sizes

• 5 mg vial
• 10 mg vial
• 15 mg vial
• 20 mg vial
• 30 mg vial
• 40 mg vial
• 50 mg
• 60 mg vial
• 100 mg vial

Questions

How much water do I add to a 50 mg Tirzepatide vial?

There is no single correct amount: water changes how many units a dose is, not how many doses the vial holds. With 1 mL the vial is 50 mg/mL and 10 mg is 20 units (0.2 mL) on a U-100 insulin syringe. The units table gives 1, 2, 5 mL.

How many doses are in a 50 mg Tirzepatide vial?

20 doses at 2.5 mg, 10 doses at 5 mg, 6 doses at 7.5 mg, 5 doses at 10 mg, 4 doses at 12.5 mg, 3 doses at 15 mg.

What does 1 unit equal in a 50 mg Tirzepatide vial?

500 mcg with 1 mL, 250 mcg with 2 mL, 100 mcg with 5 mL of bacteriostatic water, on a U-100 syringe.